Revumenib (SNDX-5613) showed promise as a stand-alone treatment in the phase I/II study of patients with R/R AML who had KMT2A-r or NPM1 mutations (NCT04065399) [10]. The gene discussed is NPM1; the disease is acute myeloid leukemia.